NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026.

doi:10.6004/jnccn.2026.0007

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026.

Journal of the National Comprehensive Cancer Network : JNCCN - 1 Feb 2026

Cheng Heather H, Giri Veda N, Goggins Michael, Yurgelun Matthew B, Karlan Beth Y, Norquist Barbara S, Daly Mary B, Pal Tuya, AlHilli Zahraa, Arun Banu, Churpek Jane, Colonna Sarah, Domchek Susan M, Escobar Mauricio R, Fejerman Laura, Friedman Susan, Hagemann Andrea, Hendrix Ashley, Huo Dezheng, Hutton Mollie L, Kassem Nawal, Khan Seema, Kurian Allison W, Laronga Christine, Mak Julie S, Maxwell Kara N, McDonnell Kevin, Merajver Sofia D, Mersch Jacqueline, Offit Kenneth, Plichta Jennifer, Rash Dominique, Reiser Gwen, Senter-Jamieson Leigha, Shannon Kristen Mahoney, Welborn Jeanna, Wick Myra J, Wood Marie, Darlow Susan, Diwan Zeenat, Dwyer Mary

Abstract excerpt

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate are intended to serve as a resource for health care providers to identify individuals who may benefit from cancer risk assessment and genetic counseling and testing; help guide decisions related to genetic testing; and facilitate a multidisciplinary approach in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Genetic Counseling

Share to Genetic Predisposition to Disease

Share to Genetic Testing

Share to Ovarian Neoplasms

Share to Pancreatic Neoplasms

Share to Prostatic Neoplasms

Share to Risk Assessment

Source

Open in PubMed

Identifiers

PMID: 41671423
DOI: 10.6004/jnccn.2026.0007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026.PMID 41671423Read ↗

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.Semantic proximity Read ↗

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read ↗

NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.Semantic proximity Read ↗

Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.Semantic proximity Read ↗

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.Semantic proximity Read ↗

NSGC Practice Guideline: Risk Assessment and Genetic Counseling for Hereditary Breast and Ovarian CancerSemantic proximity Read ↗

Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In Oncology.Semantic proximity Read ↗

Consideration for Multigene Panel Testing Outside of Cancer-Specific Genetic Testing.Semantic proximity Read ↗

Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants.Semantic proximity Read ↗

Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement.Semantic proximity Read ↗

NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2021.Semantic proximity Read ↗

The guidelines for clinical practice for carriers of germline mutations in hereditary breast, ovarian, prostate, and pancreatic cancer predisposition genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 (4.2024).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.